STOCK TITAN

Collplant Biotechnologies Ltd - CLGN STOCK NEWS

Welcome to our dedicated page for Collplant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on Collplant Biotechnologies stock.

About CollPlant Biotechnologies Ltd.

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a pioneering regenerative and aesthetic medicine company that is transforming the landscape of tissue repair, organ manufacturing, and medical aesthetics. Utilizing its proprietary recombinant human collagen (rhCollagen) technology, produced through a unique plant-based genetic engineering process, CollPlant addresses critical challenges in regenerative medicine with innovative, biocompatible solutions. The company’s products are designed to enable tissue regeneration, reduce immune response risks, and enhance patient outcomes across diverse medical fields.

Key Technologies and Products

At the heart of CollPlant’s innovation is its rhCollagen, a plant-derived, non-animal collagen that serves as the foundation for its product portfolio. This collagen is recognized for its superior biocompatibility, safety, and ability to support tissue regeneration. The company’s flagship offerings include:

  • rhCollagen BioInk: A cutting-edge bioink tailored for 3D bioprinting of tissues and organs. This bioink is a cornerstone for advancing organ manufacturing and regenerative medicine.
  • Regenerative Breast Implants: A revolutionary solution in development, designed to regenerate natural breast tissue without eliciting immune responses. These implants target the $3 billion global breast implant market, providing a safer and more natural alternative to silicone implants.
  • Vergenix™ STR: A soft tissue repair matrix for treating tendinopathy, combining rhCollagen with platelet-rich plasma (PRP) to promote healing and tendon repair.
  • Vergenix™ FG: A wound repair matrix that accelerates the healing of acute and chronic wounds by providing a supportive scaffold for cell growth.
  • Photocurable Dermal Filler: A next-generation filler under development for the medical aesthetics market, offering tissue regeneration and superior skin lifting capacity.

Strategic Collaborations

CollPlant has established strategic partnerships with industry leaders to accelerate innovation and commercialization. Notable collaborations include:

  • AbbVie: A global commercialization agreement for dermal and soft tissue fillers, leveraging CollPlant’s rhCollagen technology and AbbVie’s expertise in aesthetics.
  • Stratasys: A joint development initiative to create bioprinting solutions for regenerative breast implants, utilizing Stratasys’ P3 technology and CollPlant’s bioinks.

Market Potential and Competitive Edge

CollPlant operates in high-growth markets, including regenerative medicine, medical aesthetics, and orthobiologics. Its unique value proposition lies in its plant-based rhCollagen, which offers significant advantages over traditional animal-derived collagen, including reduced risk of immune reactions and enhanced biocompatibility. By addressing unmet needs in tissue repair and organ manufacturing, CollPlant is well-positioned to capitalize on opportunities in multi-billion-dollar markets.

Challenges and Future Outlook

While CollPlant’s innovative technology provides a competitive edge, the company faces challenges such as scaling production, navigating complex regulatory pathways, and maintaining its financial runway. However, its strong pipeline, strategic partnerships, and focus on sustainability—evidenced by its Environmental, Social, and Governance (ESG) initiatives—underscore its commitment to long-term growth and innovation.

Conclusion

CollPlant Biotechnologies Ltd. is at the forefront of ushering in a new era of regenerative medicine. Its proprietary rhCollagen technology, coupled with strategic collaborations and a robust product pipeline, positions it as a transformative player in the fields of tissue repair, organ manufacturing, and medical aesthetics. By addressing critical unmet needs with innovative, biocompatible solutions, CollPlant is poised to make a lasting impact on global healthcare.

News
Rhea-AI Summary

CollPlant Biotechnologies (NASDAQ: CLGN) reported a transformative 2020, with unaudited revenues of approximately $6 million, a 160% increase from 2019. The advancements stemmed from strategic collaborations, including partnerships with Allergan and United Therapeutics. Notably, Allergan's agreement utilizes CollPlant's recombinant human collagen for aesthetic applications, while the expanded deal with United Therapeutics addresses organ transplant shortages. The company maintains robust cash reserves of $50 million and no debt, reinforcing its growth potential as it enhances its regenerative medicine pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
none
-
Rhea-AI Summary

CollPlant Biotechnologies (NASDAQ:CLGN) has successfully closed a registered direct offering of 2,000,000 American Depositary Shares (ADSs) priced at $17.50 each, raising gross proceeds of $35.0 million. The funds will be utilized for general corporate purposes, including working capital and the development of regenerative and aesthetic medicine products. The offering is conducted under a shelf registration statement filed with the SEC. H.C. Wainwright & Co. served as the exclusive placement agent for this offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
-
Rhea-AI Summary

CollPlant Biotechnologies (NASDAQ:CLGN) announced a registered direct offering of 2,000,000 American Depositary Shares (ADSs) at $17.50 each, aiming to raise approximately $35 million in gross proceeds. The offering is expected to close around February 17, 2021. The net proceeds will support general corporate purposes, including working capital and the development of regenerative medicine products. H.C. Wainwright & Co. is the exclusive placement agent for this offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.16%
Tags
Rhea-AI Summary

CollPlant Biotechnologies (NASDAQ: CLGN) has secured a worldwide exclusive development and commercialization agreement with Allergan Aesthetics, part of AbbVie, for dermal and soft tissue filler products. This agreement includes an upfront payment of $14 million and potential milestone payments of up to $89 million. Allergan will utilize CollPlant's plant-derived recombinant human collagen (rhCollagen) alongside its own technologies. CEO Yehiel Tal expressed optimism for a transformative partnership, targeting a market expected to reach $10 billion by 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.09%
Tags
none
-
Rhea-AI Summary

CollPlant (NASDAQ: CLGN) has entered into a product manufacturing and supply agreement with STEMCELL Technologies, Canada's largest biotechnology company. This partnership involves the sale of CollPlant's recombinant human Type I collagen (rhCollagen) for use in cell culture media kits developed by STEMCELL. This agreement builds on their existing business relationship since 2014, aiming to enhance regenerative medicine research. STEMCELL's global distribution of these kits is expected to advance applications in stem cells, cancer, and cellular therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.46%
Tags
none
-
Rhea-AI Summary

CollPlant (NASDAQ: CLGN) reported a remarkable 511% increase in revenues for Q3 2020, totaling $4.1 million, up from $679,000 in Q3 2019. The company's comprehensive income reached $703,000 on a GAAP basis, or $1.1 million non-GAAP, significantly improving from a loss of $3.2 million in the same quarter last year. Cash and equivalents stood at $5.0 million. The strong financial performance is attributed to the collaboration with United Therapeutics and advancements in medical aesthetics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29%
Tags
Rhea-AI Summary

CollPlant (NASDAQ: CLGN) announced the early development of an antiviral agent utilizing its recombinant human type I collagen (rhCollagen) embedded with silver nanoparticles (AgNP) for potential COVID-19 treatment. Initial in-vitro results show significant inhibition of avian coronavirus infectivity, a model for SARS-CoV-2. The company plans to develop an inhalation formulation aimed at protecting respiratory systems, which could help reduce transmission and severity of COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
covid-19
-
Rhea-AI Summary

CollPlant (NASDAQ: CLGN), a regenerative medicine company, announced a significant first order for its Vergenix Flowable Gel product in Ukraine, amounting to hundreds of thousands of dollars. The order comes from a new Russian-based distributor and will see shipments start in the current quarter. This follows a recent distribution agreement covering six Commonwealth of Independent States countries. Vergenix FG is designed for treating difficult wounds, enhancing patient care in Ukraine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
none
-
Rhea-AI Summary

CollPlant (NASDAQ: CLGN) presented its plant-derived recombinant human collagen (rhCollagen) technology at the Science of Aging Virtual Symposium 2020. Dr. Nadav Orr discussed its applications in anti-aging therapies, highlighting the company's Skin Rejuvenation and Breast Implant pipelines. Data showed that a combination of rhCollagen and hyaluronic acid significantly enhanced the proliferation of normal human dermal fibroblasts after an 8-day treatment. The company is also focused on 3D bioprinting and has strategic partnerships with United Therapeutics and 3D Systems for developing innovative medical applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
none
Rhea-AI Summary

CollPlant (NASDAQ: CLGN) has announced a five-year distribution agreement for its Vergenix™ Flowable Gel in six CIS countries, including Belarus and Kazakhstan. The agreement includes an initial order worth hundreds of thousands of U.S. dollars. The gel is approved in Europe and is designed for treating acute and chronic wounds. A recent peer-reviewed study has shown excellent clinical outcomes for Vergenix™ FG. The company aims to expand its market presence and continue developing innovative applications for its rhCollagen technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
none

FAQ

What is the current stock price of Collplant Biotechnologies (CLGN)?

The current stock price of Collplant Biotechnologies (CLGN) is $3.17 as of March 10, 2025.

What is the market cap of Collplant Biotechnologies (CLGN)?

The market cap of Collplant Biotechnologies (CLGN) is approximately 36.7M.

What is CollPlant Biotechnologies Ltd. known for?

CollPlant Biotechnologies specializes in regenerative medicine, 3D bioprinting, and medical aesthetics using its proprietary recombinant human collagen (rhCollagen) technology.

What is rhCollagen, and why is it significant?

rhCollagen is a plant-derived, non-animal collagen developed by CollPlant. It offers superior biocompatibility and safety, making it ideal for tissue regeneration and reducing immune response risks.

What are CollPlant’s key products?

CollPlant’s portfolio includes rhCollagen BioInk for 3D bioprinting, regenerative breast implants, Vergenix™ STR for tendon repair, Vergenix™ FG for wound healing, and a photocurable dermal filler for aesthetics.

Who are CollPlant’s strategic partners?

CollPlant collaborates with AbbVie for dermal fillers and Stratasys for bioprinting solutions, leveraging their expertise to expand its product reach and market impact.

What markets does CollPlant target?

CollPlant operates in regenerative medicine, medical aesthetics, orthobiologics, and advanced wound care, addressing unmet needs in multi-billion-dollar markets.

What makes CollPlant’s products unique?

CollPlant’s plant-based rhCollagen technology offers enhanced biocompatibility, safety, and regenerative capabilities compared to traditional animal-derived collagen.

What is the significance of CollPlant’s regenerative breast implants?

CollPlant’s regenerative breast implants aim to replace silicone implants by regenerating natural breast tissue, addressing safety concerns and improving patient outcomes.

How does CollPlant generate revenue?

CollPlant generates revenue through product sales, licensing agreements, and milestone payments from strategic collaborations such as those with AbbVie and Stratasys.

What challenges does CollPlant face?

CollPlant faces challenges in scaling production, navigating regulatory pathways, and securing additional funding to support its innovative pipeline.

What are CollPlant’s sustainability initiatives?

CollPlant has implemented ESG initiatives, focusing on reducing its carbon footprint, promoting ethical governance, and enhancing social impact through sustainable practices.
Collplant Biotechnologies Ltd

Nasdaq:CLGN

CLGN Rankings

CLGN Stock Data

36.65M
7.65M
10.16%
12.23%
0.11%
Biotechnology
Healthcare
Link
Israel
Rehovot